Could a common diabetes drug weaken your bones?
NCT ID NCT00467285
First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time
Summary
This study asks whether pioglitazone, a widely used diabetes medication, might reduce bone density in people with type 2 diabetes. Researchers will compare bone mineral density and bone turnover markers in adults aged 30-55 who take pioglitazone versus those who do not. The goal is to see if the drug poses a risk to skeletal health, which could influence future treatment decisions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- pioglitazone, an oral diabetes medication
- What this could lead to
- If it works, this could clarify whether pioglitazone poses a bone risk, guiding safer diabetes treatment choices.
- What could go wrong
- This is a small, early-stage observational comparison, so results may not be conclusive or apply to all patients. Bone density changes, if any, may be modest.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOPOROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can discarded bone reveal the secrets to stronger bones?
- Could a blood flow 'Tourniquet' workout repair diabetic nerve damage?
- A tastier calcium chew might boost bone Health—But does it work?
- Exercise program aims to steady the stance of osteoporosis patients
- Can a Bone-Strengthening infusion given right after hip surgery prevent a second break?
- Can a spice and a mindset shift ease diabetic nerve pain?